



Development of RASSF1A assay:

universal fetal DNA marker

Helen White


Senior Scientist

National Genetics Reference Lab (Wessex)



Fetal specific markers

To confirm presence of cf fetal DNA if testing result is negative



Several candidates

Control Genes (limited) – will determine that cf DNA extracted but not distinguish fetal and maternal


Paternal single nucleotide polymorphisms

Epigenetic markers


No one clear approach at present – many candidate markers under development

Hypermethylated RASSFIA in Maternal Plasma: A Universal Fetal DNA Marker that Improves the Reliability of Noninvasive Prenatal Diagnosis

K.C. Allen Chan,¹ Chunming Ding,^{2,5} Ageliki Gerovassili,³ Sze W. Yeung,¹ Rossa W.K. Chiu,^{1,5} Tse N. Leung,⁴ Tze K. Lau,⁴ Stephen S.C. Chim,⁴ Grace T.Y. Chung,¹ Kypros H. Nicolaides,³ and Y.M. Dennis Lo^{1,5}*



Protocol Modifications




Chan et al. protocol (2006)

- Single enzyme digest (BstUI 60°C 16 hours)
- Probe based assay
- Beta actin promoter as digest control

Modified protocol

- Multiple enzyme digest (total digest time 4 hours)
- SYBR green assays for SRY and RASSF1A
- Melt to check amplicon specificity
- Methlyation insensitive digest control on RASSF1A
- (Beta actin promoter as digest control)



Methylation sensitive Methylation insensitive Undigested Digests RQ-PCR SRY **RASSF1A** SRY RASSF1A SRY RASSF1A $oldsymbol{ em}$ X Male fetus X V X × X **Female fetus**

X

X

×

X

X

X

X

X


X


X

X


No fetal DNA

No cell free DNA







Male fetus: SRY +ve and RASSF1A +ve




RASSF1A:



Female fetus: SRY -ve and RASSF1A +ve



No fetal DNA: SRY -ve and RASSF1A -ve



Future work

- NGRL (W) / RAPID validation ongoing
- Retrospective study of 66 samples analysis near completion

Undigested Samples (total cell free DNA): 100% had 3 replicates +ve

Methylation sensitive (fetal DNA only)

```
5 (7.5%) 3 replicates negative (no fetal DNA)
61 (92%) 1 or more replicates +ve
54 (83%) 2 or more replicates +ve
48 (72%) 3 replicates +ve
```

Methylation insensitive (all DNA should digest)

```
61 (92%) 3 replicates negative 5 (7.5%) 1 replicate +ve
```

- Prospective study of 100 samples underway using larger volume of plasma
- Assessment of RASSF1A and beta actin digests what combination is most useful / appropriate control
- Best practice?



Acknowledgements



NGRL (Wessex)

Dr Carolyn Dent Mrs Vicky Hall Mr Joe Gosling Dr John Crolla Prof Nick Cross

Institute of Child Health

Prof Lyn Chitty

Funding
NIHR
Department of Health



